- Home
- GIFT vs RNXT Comparison
GIFT vs RNXT Comparison
Compare GIFT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIFT | RNXT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 37.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GIFT | RNXT |
|---|---|---|
| Price | $0.87 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 28.8K | ★ 160.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,000.00 |
| Revenue This Year | N/A | $2,995.35 |
| Revenue Next Year | $7.20 | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.70 |
| 52 Week High | $2.38 | $1.45 |
Technical Indicators
Market Signals| Indicator | GIFT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 37.87 |
| Support Level | $0.86 | $0.82 |
| Resistance Level | $1.15 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.76 | 11.39 |
Price Performance
Historical ComparisonAbout GIFT RDE Inc.
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.